Gefitinib in recurrent glioblastoma.
Pfeffer
M Raphael
MR
Levitt
Mark L
ML
Aderka
Dan
D
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D023381:Endpoint Determination; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use*; D015203:Reproducibility of Results
D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib